Zydus Lifesciences’ Verapamil Approval Analyzed

Zydus Lifesciences has just gotten the green light from the U.S. Food and Drug Administration (FDA) to sell Verapamil Hydrochloride Extended-Release Tablets. These tablets come in strengths of 120 mg, 180 mg, and 240 mg. They are a generic version of a medicine already used to treat high blood pressure, reducing the risk of serious heart problems like strokes and heart attacks.

• Significant FDA approval for Verapamil Hydrochloride ER Tablets.
• $24.5 million annual sales in the U.S. market, growing steadily.
• 428 total approvals, showcasing Zydus’s successful drug development.
• Zydus’s overall revenue jumped 18% to $6.038 billion in Q2 FY26.
• Net profit soared 38% to Rs 1,258.60 crore in Q2 FY26.
• Zydus employs over 27,000 people globally, focused on healthcare.

This approval means Zydus will be making these tablets at its factory in Baddi, India. Sales of Verapamil Hydrochloride ER Tablets are currently selling for approximately $24.5 million annually in the United States. This growth demonstrates the demand for effective treatments for high blood pressure.

Zydus Lifesciences has gained 428 approvals overall since starting this process in 2003-2004. The company’s goal is to create new medicines and improve people’s health. They have over 27,000 employees worldwide, working hard to develop and deliver quality healthcare solutions.

Most recently, Zydus reported a strong financial performance, with a 38% increase in net profit (Rs 1,258.60 crore) and a 18% rise in revenue (Rs 6,037.9 crore) for Q2 FY26. The company’s stock price closed at Rs 928 on the BSE, reflecting investor confidence.

This approval reinforces Zydus Lifesciences’ commitment to providing accessible and effective treatments for cardiovascular health.